← Back to Treatments
🏅 FDA Orphan Designation

Lamictal

Lamotrigine

Manufacturer: Glaxo Wellcome Research and Development

Indicated for:
Lennox-Gastaut syndromeOrphanEating reflex epilepsyEpilepsy with generalized tonic-clonic seizures alone
⚠️

Black Box Warning (Boxed Warning)

A Boxed Warning is the FDA's strongest safety warning — it indicates serious or life-threatening risks identified during clinical trials or post-market surveillance. It does not mean the medication is unsafe for all patients; your prescriber weighs these risks against the benefits for your specific situation. Source: FDA-approved prescribing information.

View full prescribing information on DailyMed (NLM) ↗

FDA-Approved Indications (3)

Lennox-Gastaut syndromeOrphan Designation

Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.

adjunctive therapy for partial-onset seizures with or without secondary generalization in patients aged 13 years and older

Population: pediatric ≥13 years and adults

adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) in patients aged 13 years and older

Population: pediatric ≥13 years and adults

Indications & Usage

1 INDICATIONS AND USAGE LAMICTAL XR is indicated for: • adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) • conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 ) 1.1 Adjunctive Therapy LAMICTAL XR is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. 1.2 Monotherapy LAMICTAL XR is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Safety and effectiveness of LAMICTAL XR have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.3 Limitation of Use Safety and effectiveness of LAMICTAL XR for use in patients younger than 13 years have not been established.

💙 Support Programs

View all →
Lamictal
Glaxo Wellcome Research and Development
Lamictal
Glaxo Wellcome Research and Development
Lamotrigine
Endo USA, Inc.
Apply ↗
LAMICTAL XR
GlaxoSmithKline
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.